Hill Investment Group Partners LLC Trims Holdings in Eli Lilly and Company (NYSE:LLY)

Hill Investment Group Partners LLC reduced its stake in Eli Lilly and Company (NYSE:LLY) by 2.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 778 shares of the company’s stock after selling 21 shares during the quarter. Hill Investment Group Partners LLC’s holdings in Eli Lilly and Company were worth $711,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of LLY. Hilltop Holdings Inc. increased its holdings in shares of Eli Lilly and Company by 118.4% during the 3rd quarter. Hilltop Holdings Inc. now owns 7,328 shares of the company’s stock worth $6,492,000 after buying an additional 3,972 shares during the last quarter. Hollow Brook Wealth Management LLC grew its position in Eli Lilly and Company by 84.6% in the third quarter. Hollow Brook Wealth Management LLC now owns 480 shares of the company’s stock worth $425,000 after acquiring an additional 220 shares during the period. Holocene Advisors LP increased its stake in Eli Lilly and Company by 257.1% during the third quarter. Holocene Advisors LP now owns 437,603 shares of the company’s stock worth $387,690,000 after acquiring an additional 315,065 shares during the last quarter. Garden State Investment Advisory Services LLC raised its position in Eli Lilly and Company by 16.4% in the third quarter. Garden State Investment Advisory Services LLC now owns 2,634 shares of the company’s stock valued at $2,338,000 after purchasing an additional 372 shares during the period. Finally, Concentric Capital Strategies LP lifted its stake in shares of Eli Lilly and Company by 11.0% in the 3rd quarter. Concentric Capital Strategies LP now owns 20,110 shares of the company’s stock valued at $17,816,000 after purchasing an additional 1,991 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have commented on LLY. Berenberg Bank upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Wolfe Research began coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price on the stock. Finally, Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $800.05 on Tuesday. The firm has a market capitalization of $759.50 billion, a PE ratio of 86.49, a price-to-earnings-growth ratio of 3.01 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The business’s fifty day moving average price is $851.90 and its 200 day moving average price is $870.85.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same period in the previous year, the company posted $0.10 earnings per share. Eli Lilly and Company’s revenue was up 20.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Eli Lilly and Company will post 13.2 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.